 BAY 43-9006 SORAFENIB is a novel dual-action Raf kinase and VEGFR inhibitor, which is orally available and has a favorable safety profile in patients with advanced solid tumors. This, together with the antitumor activity observed after treatment with BAY 43-9006 SORAFENIB, provides a rationale for further evaluation in patients with advanced cancer. The recommended dose of BAY 43-9006 SORAFENIB for future studies is 400 mg bid as a continuous dosing schedule. 